The U.S. Court of Appeals for the Federal Circuit reversed-in-part, vacated-in part and remanded a prior ruling from the United States District Court for the District of Delaware in No. 1:21-cv-01594-GBW, a suit between Avadel Pharmaceuticals (AVDL) and Jazz Pharmaceuticals (JAZZ), according to a post to the appeals court’s site. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on AVDL: Disclaimer & DisclosureReport an Issue Is AVDL a Buy, Before Earnings? Avadel, nference announce publication of data on sodium oxybate Avadel Highlights Improved Demand for LUMRYZ at Conference Avadel expects to generate sustainable positive cash flow in 2025 Avadel Pharmaceuticals announces publications in CNS Drugs supplement View Comments
Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...